LLY

1,005.9

-0.62%↓

JNJ

202.13

-0.25%↓

ABBV

226.57

-0.78%↓

UNH

330.7

-0.27%↓

AZN

90.21

-0.08%↓

LLY

1,005.9

-0.62%↓

JNJ

202.13

-0.25%↓

ABBV

226.57

-0.78%↓

UNH

330.7

-0.27%↓

AZN

90.21

-0.08%↓

LLY

1,005.9

-0.62%↓

JNJ

202.13

-0.25%↓

ABBV

226.57

-0.78%↓

UNH

330.7

-0.27%↓

AZN

90.21

-0.08%↓

LLY

1,005.9

-0.62%↓

JNJ

202.13

-0.25%↓

ABBV

226.57

-0.78%↓

UNH

330.7

-0.27%↓

AZN

90.21

-0.08%↓

LLY

1,005.9

-0.62%↓

JNJ

202.13

-0.25%↓

ABBV

226.57

-0.78%↓

UNH

330.7

-0.27%↓

AZN

90.21

-0.08%↓

Начало・Списък с акции・Fulgent Genetics Inc

Fulgent Genetics Inc

Отворен

СекторЗдравеопазване

27.95 -1.34

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.71

Максимум

28.29

Ключови измерители
By Trading Economics
Приходи	12M -6.8M
Продажби	2.3M 84M
Марж на печалбата	-8.12
Служители	1,313
EBITDA	15M -77K

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+14.84% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	174M 882M
Предишно отваряне	29.29
Предишно затваряне	27.95

Настроения в новините

By Acuity

50%

178 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

17.32 / 19.04 Подкрепа & съпротива

Fulgent Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.12.2025 г., 20:41 ч. UTC

Печалби

Значими двигатели на пазара

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4.12.2025 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4.12.2025 г., 17:43 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4.12.2025 г., 17:01 ч. UTC

Печалби

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Scales Hits Mark With Earnings Guidance -- Market Talk

4.12.2025 г., 21:37 ч. UTC

Печалби

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4.12.2025 г., 21:36 ч. UTC

Печалби

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4.12.2025 г., 20:04 ч. UTC

Пазарно говорене

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4.12.2025 г., 19:54 ч. UTC

Пазарно говорене

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4.12.2025 г., 19:33 ч. UTC

Пазарно говорене

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4.12.2025 г., 18:58 ч. UTC

Пазарно говорене

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4.12.2025 г., 16:33 ч. UTC

Пазарно говорене

Печалби

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Fulgent Genetics Inc Прогноза

Ценова цел

By TipRanks

14.84% нагоре

12-месечна прогноза

Среден 32.5 USD 14.84%

Висок 35 USD

Нисък 30 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Fulgent Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Fulgent Genetics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

17.32 / 19.04Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

The bullish and bearish events are balanced.

Настроение

By Acuity

178 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.